QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.073890v1 312/1/303    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nikolaidis, L. A. Articles by Shannon, R. P. Search for Related Content PubMed PubMed Citation Articles by Nikolaidis, L. A. Articles by Shannon, R. P.

CARDIOVASCULAR

Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines

Cardiovascular Research Institute, Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania (L.A.N., A.D., T.H., L.Z., Y.-T.S., R.P.S.); and University of Massachusetts School of Medicine, Worcester, Massachusetts (D.E.)

We have recently demonstrated the benefits of glucagon-like peptide-1 (GLP-1) in enhancing regional and global myocardial function after reperfusion in the clinical setting of acute myocardial infarction. We hypothesized that GLP-1 facilitates recovery from myocardial stunning after an ischemic event. To investigate this, we administered GLP-1 (1.5 pmol/kg/min) to six dogs undergoing 10-min occlusion of the left circumflex coronary artery, followed by 24-h reperfusion. We compared the responses of coronary blood flow and regional thickening of the posterior wall with a group of eight vehicle-treated dogs undergoing the same occlusion-reperfusion protocol. Although recovery of coronary blood flow was identical, regional wall motion recovery occurred significantly (^*p < 0.05) earlier (92 ± 4 versus 57 ± 5%^* at 15 min) and was complete in the GLP-1-treated dogs, whereas residual contractile dysfunction persisted in the control group (99 ± 4 versus 78 ± 3%^* at 24 h). This phenomenon was independent of changes in systemic hemodynamics or global systolic function. However, isovolumic left ventricular relaxation improved significantly in GLP-1-treated dogs. GLP-1 caused an insulinotropic effect, but no hypoglycemia. We conclude that GLP-1 enhances recovery from ischemic myocardial stunning after successful reperfusion.

Address correspondence to: Dr. Richard P. Shannon, Department of Medicine, Allegheny General Hospital, 320 East North Ave., Pittsburgh, PA 15212. E-mail: rshannon{at}wpahs.org

This article has been cited by other articles:

				K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S.-S. Bolz, D. J. Drucker, and M. Husain Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways Circulation, May 6, 2008; 117(18): 2340 - 2350. [Abstract] [Full Text] [PDF]

				T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.-T. Shen, and R. P. Shannon Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1106 - 1113. [Abstract] [Full Text] [PDF]

				L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408. [Abstract] [Full Text] [PDF]

				W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]